Epidermal growth factor receptor-targeted therapies in gastrointestinal cancer: The story so far

Advances in Gastrointestinal Cancers

Volumn 5, Issue 2, 2007, Pages 1-2

  Watkins, David ^a   Cunningham, David ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER COMBINATION CHEMOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DIGESTIVE SYSTEM CANCER; EDITORIAL; ESOPHAGUS CANCER; HUMAN; PANCREAS CANCER; UNSPECIFIED SIDE EFFECT;

EID: 34548787728     PISSN: 14799995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (4)

1. Gill G, Kawamoto T, Cochet C et al. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem, 1984, 259, 7755-7760.
2. Masui H, Kawamoto T, Sato JD et al. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res, 1984, 44, 1002-1007.
3. Van Cutsem E, Nowacki M, Lang I et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. Proc ASCO, 2007, 25, Abstr. 4000.
4. Philip PA, Benedetti J, Fenoglio-Preiser C et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. Proc ASCO, 2007, 25, Abstr. LBA4509.